A61K31/46

Methods of treating hepatic encephalopathy
11633384 · 2023-04-25 · ·

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Methods of treating hepatic encephalopathy
11633384 · 2023-04-25 · ·

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
11633397 · 2023-04-25 ·

This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
11633397 · 2023-04-25 ·

This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

Device and method for monitoring and treating advanced bradycardia
11471657 · 2022-10-18 · ·

A device and method for monitoring the heart rate of a patient for a bradyarrhythmia event and thereafter administering medications is disclosed. The method comprises the steps of monitoring heart rate via at least one sensor secured to the neck or head of a patient; and if a bradyarrhythmia event is determined; applying an anticholinergic medication to the conjunctiva of at least one eye and releasing ammonia vapor in close proximity to the nostrils of a patient.

Device and method for monitoring and treating advanced bradycardia
11471657 · 2022-10-18 · ·

A device and method for monitoring the heart rate of a patient for a bradyarrhythmia event and thereafter administering medications is disclosed. The method comprises the steps of monitoring heart rate via at least one sensor secured to the neck or head of a patient; and if a bradyarrhythmia event is determined; applying an anticholinergic medication to the conjunctiva of at least one eye and releasing ammonia vapor in close proximity to the nostrils of a patient.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
20230062844 · 2023-03-02 ·

Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
20230062844 · 2023-03-02 ·

Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
20230062844 · 2023-03-02 ·

Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

COMPOSITIONS AND METHODS FOR MYOPIA CONTROL AND ORTHOKERATOLOGY LENSES TREATMENT

Provided herein are certain ophthalmic formulations for post-operative ocular care.